HOME >> MEDICINE >> NEWS
Initial chemotherapy treatment reduces relapses in MS patients

DENVER, CO Mitoxantrone, a chemical routinely used to fight breast cancer, leukemia and malignant lymphoma, has found a new disease to battle: Multiple Sclerosis. Used in an initial intensive course of chemotherapy (induction therapy), mitoxantrone dramatically decreases disease activity in MS patients for at least four years, according to a study presented at the Annual Meeting of the American Academy of Neurology.

Induction therapy, frequently used against cancers, is designed to wipe out abnormal cells and allow for the regrowth of normal cells. Mitoxantrone for the treatment of MS has recently been approved by the U.S. Food and Drug Administration. It has been used to treat MS in France for more than a decade. Researchers from CHU Pontchaillou of Rennes, France, have demonstrated that mitoxantrone induction therapy for relapsing-remitting MS patients has produced dramatic results in disease activity.

Over the past ten years, 100 worsening relapsing-remitting MS patients were given initial mitoxantrone induction therapy for six months, with mitoxantrone combined with methylprednisolone administered intravenously on a monthly schedule. The annual relapse rate decreased significantly from 3.20 during the 12 months preceding mitoxantrone onset to 0.30 during the first year following induction onset, corresponding to a reduction of nearly 90 percent that was maintained for more than five years. The percentage of relapse-free patients was 76 percent at one year of follow-up, and was maintained at 64 percent, 45 percent, and 43 percent at years two, three and four, respectively, with a median time to the first relapse of 2.8 years.

The clinical benefit and reduction of disease activity supports our belief that mitoxantrone, as administered in this study, may be an effective induction treatment before initiating other long-term disease modifying therapies for worsening relapsing-remitting MS patients, commented study author Emmanuelle Le Pa
'"/>

Contact: Cheryl Alementi
calementi@aan.com
651-695-2737
American Academy of Neurology
17-Apr-2002


Page: 1 2

Related medicine news :

1. Initial findings of first comprehensive study into ageing process published
2. Initial Avon/NCI breast cancer research grants awarded in Progress for Patients awards program
3. Initially recommended drug dosages often too high, study finds
4. Initial clinical study shows safety and bioactivity of cancer vaccine
5. Bevacizumab combined with chemotherapy prolongs survival for some patients with advanced lung cancer
6. Breakthrough in medical research: New chemotherapy gives hope to brain tumour patients
7. MRI better than current standard in assessing neoadjuvant chemotherapy for breast cancer
8. Older women can benefit from chemotherapy to treat breast cancer
9. Resistance to chemotherapy
10. New treatment rivals chemotherapy for lymphoma, U-M study finds
11. Adding radiation therapy to chemotherapy improves survival in patients with high-risk breast cancer

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Initial chemotherapy treatment reduces relapses patients

(Date:4/26/2015)... Italian public health researchers have released new data ... and other asbestos-related industries. Surviving Mesothelioma has just posted ... to read it now. , University researchers ... Medicine analyzed more than 15,000 cases of mesothelioma between ... asbestos cancer was most common. , “Asbestos cement ...
(Date:4/26/2015)... (PRWEB) April 26, 2015 From March ... and his wife, Trivedi Master™ Dahryn Trivedi, spent a ... approved research laboratories and institutions in the efforts of ... medicine and nutraceutical supplements for human health care. ... different research labs and institutions. All lab facilities are ...
(Date:4/26/2015)... Rosa, CA (PRWEB) April 26, 2015 In ... from Washington State University evaluated the head-neck biomechanics occurring during ... of the study were able to determine that use of ... much as 3 to 5 times - more than when ... surprising outcome for such a study, but pointing out the ...
(Date:4/25/2015)... April 26, 2015 The National ... , a national endeavor to prepare nurses to provide ... a great success, according to a new report by ... original funding partners. , The project began in ... (CCP), under the direction of Elaine Tagliareni, EdD, RN, ...
(Date:4/25/2015)... The Hon. Ellen Tauscher, Independent Chair of the ... following the deadly earthquake in Nepal: , "Today a ... deaths of more than 1,000 people. The aftershocks ... India and other parts of South Asia. I ... of Nepal and the families of the victims. ...
Breaking Medicine News(10 mins):Health News:New Investigation Finds Mesothelioma “Clusters” Around Italian Cement Plants, According to Surviving Mesothelioma 2Health News:Trivedi Science™ Has Started Scientific Research to Create More Effective Pharmaceuticals and Nutraceuticals 2Health News:Trivedi Science™ Has Started Scientific Research to Create More Effective Pharmaceuticals and Nutraceuticals 3Health News:Avoiding the Pain in the Neck Caused by Overuse of Technology 2Health News:Avoiding the Pain in the Neck Caused by Overuse of Technology 3Health News:Avoiding the Pain in the Neck Caused by Overuse of Technology 4Health News:Hartford Foundation Report Details Success of NLN's Advancing Care Excellence for Seniors (ACE.S) Program 2Health News:Hartford Foundation Report Details Success of NLN's Advancing Care Excellence for Seniors (ACE.S) Program 3
(Date:4/24/2015)...  Perrigo Company plc ("Perrigo" or the "Company") (NYSE: ... offer from Mylan NV ("Mylan") (NASDAQ: MYL ) ... for $60.00 per share in cash and 2.2 Mylan ... The Board previously concluded that Mylan,s ... Company and its future growth prospects and was not ...
(Date:4/24/2015)... , April 24, 2015  IGI Laboratories, Inc. (NYSE ... based specialty generic pharmaceutical company, announced the Company will ... Tuesday, April 28, 2015 to discuss the 1st quarter ... listen to the call by dialing 1-888-346-3479. International participants ... should ask to be joined into the IGI Laboratories, ...
(Date:4/24/2015)...  Span-America Medical Systems, Inc. (NASDAQ:  SPAN) announced ... second quarter results on Thursday, April 30, after the ... will conduct a conference call at 10:00 a.m. ... financial and operating results for the second quarter ended ... conference call will be available online at ...
Breaking Medicine Technology:Perrigo Rejects Mylan Unsolicited Offer 2Perrigo Rejects Mylan Unsolicited Offer 3Perrigo Rejects Mylan Unsolicited Offer 4
Cached News: